Ovid Therapeutics Inc. financial data

Symbol
OVID on Nasdaq
Industry
Pharmaceutical Preparations
Location
441 Ninth Avenue, 14 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 655 % -42.7%
Debt-to-equity 42.6 % +40.2%
Return On Equity -33.9 % +31.8%
Return On Assets -23.8 % +37.7%
Operating Margin -10.9K % +27.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.1M shares +0.52%
Common Stock, Shares, Outstanding 71M shares +0.45%
Entity Public Float 45.9M USD -76%
Common Stock, Value, Issued 71K USD 0%
Weighted Average Number of Shares Outstanding, Basic 71M shares +0.51%
Weighted Average Number of Shares Outstanding, Diluted 71M shares +0.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 566K USD +44.4%
Research and Development Expense 36.8M USD +28.6%
General and Administrative Expense 25.7M USD -17.4%
Operating Income (Loss) -61.9M USD -4.39%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -26.4M USD +49.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -26.4M USD +49.5%
Earnings Per Share, Basic -0.46 USD/shares +33.3%
Earnings Per Share, Diluted -0.46 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.3M USD -2.74%
Cash, Cash Equivalents, and Short-term Investments 53.1M USD -49.9%
Assets, Current 55.9M USD -49%
Property, Plant and Equipment, Net 433K USD -43.7%
Operating Lease, Right-of-Use Asset 12.8M USD -7.9%
Other Assets, Noncurrent 92K USD -56.2%
Assets 92.2M USD -36%
Accounts Payable, Current 3.19M USD -13.8%
Employee-related Liabilities, Current 2.96M USD -30.8%
Accrued Liabilities, Current 5.99M USD -8.12%
Liabilities, Current 10.5M USD -8.29%
Operating Lease, Liability, Noncurrent 13.4M USD -9.06%
Liabilities 23.9M USD -57.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -35K USD -3600%
Retained Earnings (Accumulated Deficit) -304M USD -9.51%
Stockholders' Equity Attributable to Parent 68.2M USD -22.3%
Liabilities and Equity 92.2M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.7M USD -37.8%
Net Cash Provided by (Used in) Financing Activities 228K USD +240%
Net Cash Provided by (Used in) Investing Activities 20.2M USD -33.2%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 71M shares +0.45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.2M USD -2.55%
Deferred Tax Assets, Valuation Allowance 89.5M USD -3.41%
Deferred Tax Assets, Gross 92.6M USD +25.7%
Depreciation 400K USD 0%
Payments to Acquire Property, Plant, and Equipment 19K USD +35.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26.5M USD +49.4%
Lessee, Operating Lease, Liability, to be Paid 19.3M USD -10.7%
Operating Lease, Liability, Current 1.34M USD +7.22%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.32M USD -0.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.32M USD -0.01%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.32M USD -0.01%
Deferred Tax Assets, Operating Loss Carryforwards 62.1M USD +11.6%
Preferred Stock, Shares Issued 1.25K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.47M USD +6.59%
Additional Paid in Capital 372M USD +1.89%
Preferred Stock, Shares Outstanding 1.25K shares 0%
Amortization of Intangible Assets 200K USD +100%
Depreciation, Depletion and Amortization 136K USD -6.21%
Share-based Payment Arrangement, Expense 6.28M USD -13.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%